Trademark: 78543928
Word
FLASHDOSE
Status
Dead
Status Code
606
Status Date
Monday, August 24, 2009
Serial Number
78543928
Mark Type
4000
Filing Date
Friday, January 7, 2005
Published for Opposition
Tuesday, May 2, 2006
Abandoned Date
Monday, August 24, 2009

Trademark Owner History
BIOVAIL LABORATORIES INTERNATIONAL SRL - 1st New Owner After Publication
Biovail Laboratories, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan
FLASH DOSE

Trademark Events
Oct 13, 2010
Assignment Of Ownership Not Updated Automatically
Aug 24, 2009
Abandonment Notice Mailed - No Use Statement Filed
Aug 24, 2009
Abandonment - No Use Statement Filed
Jun 17, 2009
Assignment Of Ownership Not Updated Automatically
Feb 5, 2009
Extension 5 Granted
Jan 22, 2009
Extension 5 Filed
Feb 5, 2009
Case Assigned To Intent To Use Paralegal
Jan 22, 2009
Teas Extension Received
Jan 22, 2009
Applicant/Correspondence Changes (Non-Responsive) Entered
Jan 22, 2009
Teas Change Of Owner Address Received
Jul 17, 2008
Extension 4 Granted
Jul 17, 2008
Extension 4 Filed
Jul 17, 2008
Teas Extension Received
Feb 7, 2008
Extension 3 Granted
Jan 18, 2008
Extension 3 Filed
Jan 18, 2008
Teas Extension Received
Sep 29, 2007
Teas Change Of Correspondence Received
Sep 14, 2007
Extension 2 Granted
Jul 12, 2007
Extension 2 Filed
Jul 12, 2007
Teas Extension Received
Dec 27, 2006
Extension 1 Granted
Nov 9, 2006
Extension 1 Filed
Nov 9, 2006
Teas Extension Received
Jul 25, 2006
Noa Mailed - Sou Required From Applicant
May 2, 2006
Published For Opposition
Apr 12, 2006
Notice Of Publication
Mar 14, 2006
Law Office Publication Review Completed
Mar 10, 2006
Assigned To Lie
Mar 8, 2006
Approved For Pub - Principal Register
Mar 3, 2006
Teas/Email Correspondence Entered
Feb 9, 2006
Correspondence Received In Law Office
Feb 9, 2006
Teas Response To Office Action Received
Aug 9, 2005
Non-Final Action E-Mailed
Aug 9, 2005
Non-Final Action Written
Aug 9, 2005
Assigned To Examiner
Apr 13, 2005
Teas Change Of Correspondence Received
Jan 19, 2005
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24